Inactive Instrument

Analyst Reco. OYSR POIN

Equities

Piper Sandler Downgrades Oyster Point Pharma to Neutral From Overweight, Adjusts Price Target to $11 From $15	22-11-08	MT
Chardan Downgrades Oyster Point Pharma to Neutral From Buy on Proposed Sale to Viatris, Trims Price Target to $13 From $22	22-11-08	MT
Chardan Research Starts Oyster Point Pharma at Buy With $22 Price Target	22-08-11	MT
HC Wainwright Initiates Oyster Point Pharma at Buy With $20 Price Target	22-07-18	MT
Piper Sandler Adjusts Price Target on Oyster Point Pharma to $15 From $60, Reiterates Overweight Rating	22-05-31	MT
JPMorgan Lowers Oyster Point Pharma to Neutral From Overweight, Price Target to $23 From $30	21-11-09	MT

No results for this search